News >

Rituximab Maintenance After ASCT Prolongs Survival in MCL

Jason Harris
Published: Thursday, Oct 19, 2017

Steven Le Gouill, MD, PhD
Steven Le Gouill, MD, PhD
Maintenance rituximab (Rituxan) following autologous stem-cell transplantation (ASCT) improved survival in younger patients with mantle cell lymphoma (MCL), according to results from the phase III phase III LyMa trial published in the New England Journal of Medicine.

= .04).
Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250-1260. doi:10.1056/NEJMoa1701769.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x